Overview

Brimonidine 0.1% Versus Brinzolamide 1% as Adjunctive Therapy to Latanoprost 0.005%

Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
Patients with glaucoma or ocular hypertension currently being treated with latanoprost 0.005%, and in need of additional IOP lowering will be randomized to receive either brimonidine 0.1% or brinzolamide 1% three-times daily as adjunctive therapy to latanoprost 0.005%
Phase:
Phase 4
Details
Lead Sponsor:
Allergan
Treatments:
Brimonidine Tartrate
Brinzolamide
Latanoprost
Ophthalmic Solutions
Tetrahydrozoline